Active, Not Recruiting

NCT Number: NCT07398261

Efficacy of Mirabegron for Treatment of Non-monosymptomatic Nocturnal Enuresis in Children

This phase 3 clinical trial will compare use of individual treatment with mirabegron or desmopressin and their combination for treatment of non-monosymptomatic nocturnal enuresis in children

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Treatment of Non-monosymptomatic Nocturnal Enuresis

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Menoufia faculty of medicine

Shibīn al Kawm, Monufia Governorate, 32616, Egypt

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Non-monosymptomatic nocturnal enuresis

Exclusion criteria

monosymptomatic nocturnal enuresis

Treatment and study plan

Mirabegron 25 MG

Drug

Evaluate the efficacy of individual mirabegron or in combination for treatment of non-monosymptomatic nocturnal enuresis in children

Other names: vibegron

Primary outcomes

Partial or complete response

Time frame: 18 months

Sponsors and collaborators

Lead sponsor

Menoufia University

Other

Registry information

Important dates

Study start: 2023
Primary completion: 2026
Study completion: 2026
First posted: Feb 9, 2026
Registry last updated: Feb 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.